{"schema_version":"secwatch.filing_event.v1","accession":"0001870940-24-000028","form_type":"8-K","ticker":"AIRS","cik":"0001870940","company_name":"Airsculpt Technologies, Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.033777+00:00","generated_at":"2026-06-02T04:14:38.772509+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AirSculpt Q1 revenue up 3.9% to $47.6M; net income $6M; adjusted EBITDA down to $7.3M; reaffirms FY guidance","bullets":["Cases 3,746 (+2.9% YoY); revenue $47.6M (+3.9%); net income $6.0M vs. $0.0M loss prior year; diluted EPS $0.10.","Adjusted EBITDA $7.3M vs. $9.5M prior year, decline from customer acquisition investment and macro headwinds.","FY 2024 guidance maintained: revenue ~$220M, adjusted EBITDA ~$50M, ~65% cash conversion ratio, six new centers in H2.","Pre-opening de novo and relocation costs $0.0M vs. $1.3M in prior year; no new centers opened in Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0001870940-24-000028","json":"https://secwatch.observer/filing/0001870940-24-000028.json","markdown":"https://secwatch.observer/filing/0001870940-24-000028.md","text":"https://secwatch.observer/filing/0001870940-24-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870940/000187094024000028/0001870940-24-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870940/000187094024000028/airs-20240510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:14:38.772509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b91bfaed5f21ff2c94d553a57d799ea3e16e4c0b","claim":"Airsculpt Technologies, Inc. reported first quarter ended March 31, 2024 results: revenue $47.6 million, net income $6.0 million, EPS $0.10. Guidance reaffirmed.","evidence_excerpt":"results for the first quarter ended March 31, 2024. First Quarter • Cases increased 2.9% over the prior year period to 3,746 • Revenue increased 3.9% over the prior year to $47.6 million • Net income of $6.0 million for the quarter compared to $(0.0) million in the prior year period • Diluted income per share for the quarter of $0.10 • Six planned openings in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870940/000187094024000028/0001870940-24-000028-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$47.6 million"},{"label":"Net income","value":"$6.0 million"},{"label":"EPS","value":"$0.10"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}